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Purpose of the study
HIV/HCV co-infection is highly prevalent in Spain (50%–
60%), and liver disease is the leading cause of morbidity
and mortality among those individuals. Currently, liver
biopsy is considered to be the gold standard for assessing
significant liver fibrosis in the context of HCV-related liver
disease. Multiple biopsies are impractical, costly, and
could lead to infrequent but serious complications, how-
ever, non-invasive measures of liver fibrosis could there-
fore offer significant advantages. The objective of this
cross-sectional study was to estimate the prevalence of sig-
nificant liver fibrosis (SLF) in HIV/HCV patients in Spain
using APRI and Forns index.
Methods
Patients are considered to have SLF if they have an APRI
score >1.5 or an APRI score <1.5 but a Forns index score
>6.9. Data from Fibroscan and biopsies were collected
when available.
Summary of results
Results from 8,829 evaluable patients (78.3% male) have
been analyzed. Mean age 41.8 ± 6.2 years; 91.6% on
antiretroviral treatment (ARVT). 57.9% of the patients
were infected by HCV genotype 1, 20.5% genotype 3,
16.1% genotype 4, 3.2% genotype 2, and 2.3% other gen-
otypes. 30.6% of the patients were diagnosed of SLF
according to the APRI/Forns algorithm. Nadir CD4 cell
count was lower in patients with SLF than in those with-
out SLF, median 159 cells/mcg vs. 191 cells/mcg, respec-
tively (p < 0.001); OR (for each 100 cell increase) = 0.92
(95% CI: 0.89–0.95). SLF was also more prevalent among
male than among female patients, 32.7% vs. 23.2%,
respectively (p < 0.001); [OR 0.63 (95% CI: 0.56–0.71)].
Results from biopsy and Fibroscan were collected in 1,701
and 1,879 patients, respectively. 53.3% of the patients
had F2–F4 according to biopsy and 56.1% according to
Fibroscan (>7 kPa). The positive predictive value of the
algorithm according to biopsy results for SLF was 79.2%
(95% CI: 67.7–90.7).
Conclusion
An algorithm of biomarkers, including APRI and Forns
index, identifies a significant proportion of HIV/HCV co-
infected patients with F2–F4 liver fibrosis in daily clinical
practice, although its performance is slightly lower than
that reported in prior validation studies. Immunodepres-
sion and male sex are the main factors associated with sig-
nificant fibrosis assessed by this procedure.
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